Combination Prevention Core

摘要 CHIPTS联合预防(CP)核心促进以下干预措施的开发和评估 整合循证行为、生物医学、技术和结构组成部分以减少艾滋病毒 并优化艾滋病毒护理和预防连续工作的每一步。对战略规划的回应 以及对艾滋病毒预防的医学化的预期，国家方案核心将其资源集中于指导努力 解决包括男子在内的关键人群在获得和坚持护理和预防方面的长期差距 与有色人种男性，非裔美国女性，变性人，年轻人，无家可归者，以及 被监禁的人。在这些关键人群中，我们进一步瞄准了那些患有物质共病的人 使用和精神健康障碍以及其他干扰获得和坚持使用抗逆转录病毒药物的因素 治疗(ART)。虽然努力产生可衡量的结果(例如，抑制病毒、减少发病率) 利用抗逆转录病毒疗法预防艾滋病毒取得了显著的成功，这项研究是在人群中进行的 服药依从性。然而，在关键人群中，共病药物使用和 精神健康障碍导致艾滋病毒预防和护理连续过程中的“漏洞”。它的三个具体目标是： (1)科学：领导行为、生物医学、技术和结构相结合的科学议程 优化艾滋病毒护理和艾滋病毒预防结果的干预措施，重点是精神健康和/或有心理健康的人 国内和全球的物质使用障碍；在科学研究网络中发挥带头作用(例如，HPTN、ACTG)； (2)建立网络：召集各种活动，介绍传播和扩大 行为、生物医学、技术和结构干预；通过参与促进科学发展 调查员和社区利益攸关方；(3)能力建设：在受影响地区建设能力 社区、主要利益攸关方和服务组织通过社区教育和劳动力培训； 指导新出现的科学家和教职员工联合预防方法；促进 对艾滋病毒治疗或预防研究感兴趣的社区成员，并提供持续的研究机会。 这一科学、网络和能力建设的协调议程将产生先锋信息和 将指导在普通人群和重点人群中根除艾滋病毒的努力的专门知识。 CP核心团队由主任凯西·雷贝克博士、联席主任拉斐尔·兰多维茨医学博士、硕士和 副主任丹妮尔·哈里斯，公共卫生。核心服务包括：对组合艾滋病毒的研究提供建议 预防；在艾滋病毒预防方面就药物使用和精神健康的研究提供指导； 提供同行评审；翻译国内艾滋病毒预防战略，以便在国外环境下使用；提供建议 并培训文化能力，特别是在有共病条件的关键人群中；领导劳动力 培训；指导新兴院士。

ABSTRACT The CHIPTS Combination Prevention (CP) Core promotes development and evaluation of interventions that integrate evidence-based behavioral, biomedical, technological and structural components to reduce HIV incidence and to optimize each step of the HIV care and prevention continua. In response to strategic planning and anticipation of the medicalization of HIV prevention, the CP Core focuses its resources on guiding efforts that address persistent gaps in access and adherence to care and prevention in key populations, including men who have sex with men of color, African American women, transgender individuals, youth, homeless, and incarcerated individuals. Within these key populations, we further target those with comorbidities of substance use and mental health disorders and other factors that interfere with access and adherence to antiretroviral therapy (ART). While efforts to produce measurable outcomes (e.g., viral suppression, reduction in incidence) to HIV prevention have shown remarkable success using ART, the research was conducted on populations compliant with medications. Yet the disorganizing effects in key populations of comorbid substance use and mental health disorders contribute to “leaks” in the HIV prevention and care continua. Its three specific aims are: (1) SCIENCE: To lead the science agenda on combining behavioral, biomedical, technological and structural interventions to optimize HIV care and HIV prevention outcomes, with a focus on those with mental health and/or substance use disorders, domestically and globally; to lead in scientific research networks (e.g., HPTN, ACTG); (2) NETWORKING: To convene activities that present best practices for dissemination and scale-up of behavioral, biomedical, technological, and structural interventions; to promote science development by engaging investigators and community stakeholders; (3) CAPACITY BUILDING: To build capacity within affected communities, key stakeholders, and service organizations through community education and workforce training; to mentor emerging scientists and faculty on combination prevention approaches; to facilitate linkages between community members interested in HIV therapeutic or prevention research with ongoing research opportunities. This coordinated agenda of science, networking and capacity building will generate vanguard information and expertise that will guide efforts towards HIV eradication in both the general population and in key populations. The CP Core team is led by Director Cathy Reback, PhD, Co-Director Raphael Landovitz MD, MSc, and Associate Director Danielle Harris, MPH. Core services include: advise on research on combination HIV prevention; provide guidance on study of substance use and mental health in the context of HIV prevention; provide peer review; translate domestic HIV prevention strategies for use in foreign settings and back; advise and train cultural competence, especially in key populations with comorbid conditions; conduct workforce training; mentor emerging academicians.